Inborn errors of metabolism (IEMs) are a large group of genetic diseases in which the body can’t properly convert food into energy or building blocks for cells. Each disorder traces back to a defect in a single enzyme, cofactor, or transport protein involved in a biochemical pathway. As of June 2024, researchers have identified 1,564 distinct IEMs. Individually, each one is rare, but collectively they affect roughly 1 in every 2,000 newborns worldwide.
How These Disorders Work at a Cellular Level
Your body runs on thousands of chemical reactions that break down nutrients, build new molecules, and clear waste products. Each reaction depends on a specific protein to do its job. In an inborn error of metabolism, one of those proteins is missing, deficient, or doesn’t function correctly because of a mutation in the gene that codes for it.
The consequences follow a predictable logic. When a reaction can’t proceed, the substance that was supposed to be converted starts to pile up, sometimes reaching toxic levels. At the same time, the product that reaction was supposed to create may be in short supply. It’s like a blocked step on an assembly line: raw material backs up behind the blockage, and nothing gets delivered downstream. Depending on which pathway is affected, the toxic buildup can damage the brain, liver, heart, kidneys, or other organs, sometimes within days of birth.
Main Categories of Metabolic Disorders
With over 1,500 known conditions, IEMs are grouped by which biochemical pathway they disrupt. The major categories include:
- Amino acid disorders. These affect how the body breaks down proteins. When an enzyme in this pathway is deficient, toxic byproducts accumulate, particularly during illness or fasting when the body breaks down its own protein for energy. Phenylketonuria (PKU), the most common congenital metabolic disease, falls into this group.
- Organic acid disorders. These involve deficiencies in enzymes that process small carbon-based molecules inside mitochondria, the energy-producing structures in cells. They often produce severe acid buildup in the blood.
- Fatty acid oxidation disorders. During fasting, the body relies on stored fat for fuel, converting it into molecules called ketone bodies that power the brain and muscles. Defects in this pathway leave the body unable to tap its fat stores, which can cause dangerous drops in blood sugar and energy crises, especially during periods without food.
- Carbohydrate disorders. Classic galactosemia, for example, prevents the body from processing galactose, a sugar found in milk. It occurs in about 1 in 60,000 live births.
- Lysosomal storage disorders. These involve problems clearing large, complex molecules from cells. Without the right enzyme, these molecules accumulate inside cellular compartments and gradually damage tissues.
How They’re Inherited
Most inborn errors of metabolism follow an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy of the gene from both parents to develop the disease. Parents who each carry one defective copy typically have no symptoms themselves. Each pregnancy between two carriers has a 25% chance of producing an affected child. Some IEMs follow other patterns, including autosomal dominant inheritance or X-linked inheritance, where the defective gene sits on the X chromosome and disproportionately affects males.
Signs in Newborns and Infants
One of the trickiest aspects of IEMs is that early symptoms look a lot like other newborn problems. Common signs include lethargy, poor feeding, vomiting, weak muscle tone, irritability, pauses in breathing, and seizures. Metabolic acidosis (too much acid in the blood) and low blood sugar are frequent lab findings.
A hallmark clue that points toward a metabolic disorder rather than a birth injury or infection is the symptom-free interval. A baby with an IEM often appears healthy for the first hours or days of life, then deteriorates as toxic substances build up. That initial normal period, followed by an unexplained decline, is a key signal. Progressive worsening of neurological symptoms, an unexplained coma, unusual body odor (as in maple syrup urine disease), or an enlarged liver and spleen also raise suspicion.
Newborn Screening
Newborn screening is the single most important tool for catching IEMs before symptoms cause irreversible damage. The concept began in Europe in the 1960s with a simple blood test for PKU. Today, a few drops of blood from a heel prick are collected on a filter paper card, and a technology called tandem mass spectrometry can detect dozens of metabolic abnormalities from that single small spot of dried blood. In one run, the test screens for disorders of amino acid, fatty acid, and organic acid metabolism.
In the United States, the Recommended Uniform Screening Panel maintained by the Health Resources and Services Administration lists the conditions every state is advised to screen for. As of January 2023, the core metabolic conditions on that panel include 9 organic acid conditions, 5 fatty acid oxidation disorders, 6 amino acid disorders, and several additional conditions such as biotinidase deficiency, classic galactosemia, and Pompe disease. States vary somewhat in which conditions they actually test for, but the trend over the past two decades has been steady expansion.
Diagnosis Beyond the Heel Prick
A positive newborn screen is a flag, not a final diagnosis. Confirmatory testing typically involves analyzing amino acid and organic acid levels in blood and urine, along with genetic testing to identify the specific mutation. Stored dried blood spots from the original screening can also be reanalyzed later if a new concern arises. For some conditions, enzyme activity is measured directly from blood cells or skin samples to confirm the deficiency.
Treatment Options
Only about 275 of the 1,564 known IEMs, roughly 18%, currently have effective treatments. But for those that do, early intervention can be transformative. Treatment strategies are built around three core principles: reducing the toxic buildup, replacing what’s missing, and supplementing what the body can’t make on its own.
Dietary Management
For many IEMs, the first line of treatment is controlling what goes into the body. A child with PKU, for example, follows a strict low-protein diet for life to limit the amino acid phenylalanine, which their body can’t break down. In urea cycle disorders, protein restriction reduces the amount of ammonia the body has to process. These diets are highly specialized and require ongoing monitoring by metabolic dietitians to ensure the child still gets adequate nutrition for growth.
Substrate Reduction and Toxin Removal
When diet alone isn’t enough, medications can help reduce the production of toxic substances or speed their removal. Substrate reduction therapy uses small-molecule drugs to slow the creation of compounds that the body can’t break down. In acute metabolic crises, procedures that filter toxins from the blood may be necessary.
Enzyme Replacement and Transplantation
For some conditions, particularly lysosomal storage disorders, enzyme replacement therapy delivers a functional version of the missing enzyme directly into the bloodstream through regular infusions. The body then uses that enzyme to clear the accumulated material. In other cases, organ or cell transplantation (most commonly liver or bone marrow) can provide a lasting source of the missing enzyme. Cofactor supplementation, giving the body extra amounts of a vitamin or helper molecule that the defective enzyme needs, can boost residual enzyme activity in certain disorders.
Long-Term Outlook
Outcomes vary enormously depending on the specific condition, how early it’s detected, and whether an effective treatment exists. PKU is the clearest success story: children identified through newborn screening and placed on a managed diet from infancy develop normally and live full lives. For severe organic acidemias or urea cycle disorders, even with treatment, the risk of metabolic crises during illness or stress remains a lifelong reality, and some degree of developmental impact is common.
For the roughly 82% of IEMs without established treatments, management focuses on supportive care and symptom control. The pace of discovery, however, is accelerating. Gene therapy and newer enzyme delivery methods are in active development for a growing list of conditions, and the number of treatable IEMs has been steadily climbing as these approaches mature.